Loading
Anixa Biosciences Inc Stock: price and insider trades · United States
4 insiders bought €302k of shares over the last 90 days, the latest filed 30 Sept 2026.
Cluster: 4 buyers in 30 daysAnixa Biosciences Inc: what insiders have been doing
Anixa Biosciences Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 22 filings signed by 4 insiders.
The flow runs one way only: 4 insiders bought (18 purchases totalling €348k) and nobody sold on the market. No amount is published for 2 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. One trade stands out by size: a purchase of €115k from Titterton Lewis H jr, disclosed on 25 September 2026, or 0.14% of market capitalisation. The buyers include 2 senior executives, 1 finance chief and 1 chief executive.
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 22 filings here. Looking back to 2021, when coverage begins, insiders filed 62 purchases and no sales.
Within a 30-day window, 13 purchases overlapped with buying by a second insider. Purchases made close together by different insiders form what is called a cluster. The clock since the last published purchase (30 September 2026) now reads 18 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
82
Thresholds
n/a
Buy Volume
€2M
62 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAmit Kumar14 buys
Lewis H. Titterton Jr.11 buys
Arnold M. Baskies4 buys
Michael Catelani2 buys
Since the insiders bought
- -5.0%Entry US$2.80 · Close 14 Oct 2026 US$2.66
- -25.3%Entry US$3.56 · Close 14 Oct 2026 US$2.66
- -1.3%Entry US$3.04 · Close at T+90 US$3.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Anixa Biosciences Inc Strong Buy (bullish), based on 4 analysts. Average price target: US$9.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended October 2025 · cache
US$2.66
Analyst consensus
4 analystsStrong buy
US$6.00Target US$9.75(+267%)US$14.00
Income statement
EBITDA-US$11.7M
Net income-US$10.9M0.0% margin
Valuation
PER (forward)-8.6x
P/Book6.4x
Beta0.48
Balance sheet & cash
Market capUS$92.3M
Total debtUS$204k
Free Cash Flow-US$7.2M
Debt / Equity1%
Profitability & ownership
ROE-73.2%
ROA-41.9%
% insiders5.6%
% institutions13.9%
Last declaration on 30 September 2026
Declarations82 total
5,500 shares@ US$2.840.016% mcap13.3% of flowCommon StockSEC:0001493152-26-045053:0
Canonical exit: 29 Dec 2026 (T+90)
5,000 shares@ US$2.760.014% mcap4.3% of flowCommon StockSEC:0001493152-26-044457:0
Canonical exit: 23 Dec 2026 (T+90)
7,000 shares@ US$2.780.020% mcap0.6% of flowCommon StockSEC:0001493152-26-044458:0
Canonical exit: 23 Dec 2026 (T+90)
49,036 shares@ US$2.690.14% mcap8.2% of flowCommon StockSEC:0001493152-26-044250:0
Canonical exit: 22 Dec 2026 (T+90)
10,000 shares@ US$2.730.028% mcap1.7% of flowCommon StockSEC:0001493152-26-042502:0
Canonical exit: 9 Dec 2026 (T+90)
3,000 shares@ US$2.750.0084% mcap0.3% of flowCommon StockSEC:0001493152-26-042512:0
Canonical exit: 9 Dec 2026 (T+90)
5,000 shares@ US$2.760.014% mcap0.4% of flowCommon StockSEC:0001493152-26-042302:0
Canonical exit: 9 Dec 2026 (T+90)
5,000 shares@ US$3.470.018% mcap0.5% of flowCommon StockSEC:0001493152-26-035751:0
Canonical exit: 29 Oct 2026 (T+90)
5,428 shares@ US$3.460.020% mcap6.1% of flowCommon StockSEC:0001493152-26-035122:1
6,000 shares@ US$3.130.020% mcap6.1% of flowCommon StockSEC:0001493152-26-035122:0
5,000 shares@ US$3.440.018% mcap0.5% of flowCommon StockSEC:0001493152-26-034952:0
Canonical exit: 25 Oct 2026 (T+90)
3,000 shares@ US$3.730.012% mcap0.4% of flowCommon StockSEC:0001493152-26-034723:0
Canonical exit: 22 Oct 2026 (T+90)
3,188 shares@ US$3.370.011% mcap0.3% of flowCommon StockSEC:0001493152-26-034772:0
Canonical exit: 25 Oct 2026 (T+90)
5,000 shares@ US$3.460.018% mcap0.6% of flowCommon StockSEC:0001493152-26-034027:0
Canonical exit: 18 Oct 2026 (T+90)
12,000 shares@ US$3.470.043% mcap2.6% of flowCommon StockSEC:0001493152-26-033949:0
Canonical exit: 18 Oct 2026 (T+90)
2,797 shares@ US$3.280.0095% mcap0.6% of flowCommon StockSEC:0001493152-26-033461:0
Canonical exit: 13 Oct 2026 (T+90)
5,000 shares@ US$3.040.016% mcap0.5% of flowCommon StockSEC:0001493152-26-032961:0
Canonical exit: 8 Oct 2026 (T+90)
2,836 sharesCommon StockSEC:0001493152-26-029030:0
Canonical exit: 14 Sept 2026 (T+90)
21,000 sharesCommon StockSEC:0001493152-26-028827:0
Canonical exit: 10 Sept 2026 (T+90)
10,000 shares@ US$3.049.4% of flowCommon StockSEC:0001493152-26-004148:0
Canonical exit: 28 Apr 2026 (T+90)
16,000 shares@ US$2.922.8% of flowCommon StockSEC:0001493152-25-027904:0
200,000 shares@ US$2.9218.3% of flowCommon StockSEC:0001493152-25-020322:0
10,000 shares@ US$3.081.9% of flowCommon StockSEC:0001641172-25-022000:0
Canonical exit: 29 Oct 2025 (T+90)
5,000 shares@ US$3.160.5% of flowCommon StockSEC:0001641172-25-021679:0
Canonical exit: 28 Oct 2025 (T+90)
5,000 shares@ US$3.395.4% of flowCommon StockSEC:0001641172-25-020362:0
Canonical exit: 16 Oct 2025 (T+90)
25 of 82 declarations
About Anixa Biosciences Inc
Anixa Biosciences Inc. is a U.S.-based biotechnology company listed on the NASDAQ under the ticker ANIX. For French-speaking investors, it fits the profile of a clinical-stage oncology biotech rather than a commercial pharmaceutical company: the investment case depends primarily on scientific execution, clinical readouts, regulatory progress, and strategic partnerships. The company is headquartered in San Jose, California, placing it in one of the most active U.S. biotech and venture capital ecosystems. Anixa’s corporate roots date back to its incorporation in Delaware in 1982, and the company later rebranded as Anixa Biosciences in 2018 as it sharpened its focus on cancer-related technologies. ([anixa.com](https://www.anixa.com/?utm_source=openai))
Anixa’s business model is built around highly focused oncology innovation. Its therapeutics portfolio includes an ovarian cancer immunotherapy program based on a novel CAR-T approach known as CER-T, developed in collaboration with Moffitt Cancer Center. In parallel, the company is advancing a vaccine platform aimed at the prevention and treatment of breast cancer, especially triple-negative breast cancer, as well as ovarian cancer, through collaborations with Cleveland Clinic. Management also describes additional “retired tissue specific protein” vaccine programs that could eventually be expanded into other hard-to-treat cancers such as lung, colon, and prostate cancer. ([anixa.com](https://www.anixa.com/about?utm_source=openai))
Read moreShow less
From a competitive standpoint, Anixa is still at an early stage and does not have a marketed product franchise. Its position is therefore best understood as that of a small-cap clinical innovator competing in a crowded oncology research landscape. The company’s differentiation comes from the scientific novelty of its platforms, the intellectual property surrounding its vaccine and cell-therapy concepts, and the credibility of its academic and clinical partners. That makes the stock highly sensitive to trial results and financing conditions, while also giving it meaningful upside if one of the programs advances successfully. ([anixa.com](https://www.anixa.com/about?utm_source=openai))
Recent developments have been constructive. In 2025, Anixa reported positive Phase 1 data for its investigational breast cancer vaccine, stating that key primary endpoints were met and that immune responses were observed, supporting a move toward Phase 2 development. The company also announced a letter of intent with VERDI Solutions to develop personalized and off-the-shelf peptide vaccines for cancer patients. In 2026, Anixa highlighted encouraging survival observations from its ongoing ovarian cancer CAR-T Phase 1 study and disclosed that it received Mexican patent protection for its breast cancer vaccine technology. ([ir.anixa.com](https://ir.anixa.com/press-releases/detail/1107/anixa-biosciences-announces-positive-phase-1-data-for?utm_source=openai))
Overall, Anixa Biosciences Inc. is a United States biotech company listed on NASDAQ with a clear oncology mandate and a research-heavy profile. Its geographic footprint is still predominantly U.S.-centric, but its intellectual property and partnering strategy could support broader international relevance over time. For investors, the name represents a high-risk, high-upside exposure to cancer immunotherapy and vaccine development, with value creation tied to clinical milestones rather than current operating scale.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
